Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Pediatric Hematology/Oncology
•
Rhabdomyosarcoma
•
Pediatric Oncology
•
Oncology
Which oral chemotherapy regimen do you use in relapsed fusion positive rhabdomyosarcoma?
Related Questions
How do you approach revaccination after chemotherapy, and what labs (if any) do you use to assess immune reconstitution?
What is your approach to patients/parents seeking alternative or complementary treatment in pediatric oncology patients?
What are the main barriers you encounter in enrolling pediatric oncology patients on clinical trials?
What radiation dose and margins would you recommend for treatment of a progressive cerebellar glioma with BCOR/BCOR1 fusion after initial subtotal resection with residual disease adjacent to the posterior brainstem?
How do you determine timing, and whether or not to rechallenge a pediatric oncology patient with immune checkpoint inhibitor therapy after development of irAE?
Do you routinely use thrombopoietin receptor agonists (like romiplostim) to address chemotherapy-induced thrombocytopenia in solid tumor pediatric oncology patients?
What is your standard diagnostic workup to confirm GVHD in a patient post-BMT with skin rash and jaundice?
In platinum-refractory or multiply-relapsed NSGCT with 1–2 progressive sites and no good surgical option, is there a role for local radiotherapy (e.g., SBRT) to those sites?
Do you use prophylactic defibrotide in pediatric patients undergoing BMT who are considered to be at high risk for the development of VOD/SOS?
What role do genetic and molecular profiling play in predicting which patients with high-risk localized RMS benefit from maintenance chemotherapy with vinorelbine and low-dose cyclophosphamide?
